FDA
-
-
-
-
-
-
-
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
-
-
-
-
-
-
-
PMV Pharmaceuticals (PMVP) and Foundation Medicine Collaborate to Develop Companion Diagnostic for Rezatapopt
-
-
-
-
-
-
-
PMV Pharmaceuticals (PMVP) Announces Prioritization of PC14586 Clinical Development, Cuts 30% Staff
-
-
-
-
-
-
-
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
-
-
-
-
-
-
-
PMV Pharmaceuticals (PMVP) Appoints Carol Gallagher to its Board
-
-
-
-
-
-
-
PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
-
323,584 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

